drugset / Trial / NCT01301833

Long-term Safety Study of MP-513 in Patients With Type 2 Diabetes

NCT01301833

Phase 3 Completed 462 enrolled Tanabe Pharma Corporation
Non-randomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the safety and efficacy of MP-513 (Teneligliptin) as monotherapy or in combination with oral antihyperglycaemic agent in patients with type 2 Diabetes for 52 weeks administration.

Timeline

Start
2011-02
Primary completion
2012-09
Completion
2012-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Teneligliptin Small molecule 40 mg